MWN109 (Shanghai Minwei Biotechnology Co., Ltd.)

MWN109 is a long-acting recombinant fusion protein developed by Shanghai Minwei Biotechnology for the treatment of metabolic disorders, including obesity, overweight, and type 2 diabetes. The drug is a glucagon-like peptide-1 receptor (GLP-1R) agonist, designed using an Fc-fusion protein technology platform to extend its half-life and allow for weekly subcutaneous administration. By activating the GLP-1 receptor, MWN109 stimulates glucose-dependent insulin secretion, inhibits glucagon release, and delays gastric emptying, which collectively promotes satiety and significant weight reduction. As of 2024, MWN109 is being evaluated in Phase 3 clinical trials (e.g., CTR20242145) for efficacy and safety in non-diabetic participants with obesity or overweight. The designation "MWN109 2" specifically refers to one of the dose levels or titration cohorts investigated within these clinical trial protocols.